Log in

Axcella Health Stock Forecast, Price & News

+0.05 (+1.06 %)
(As of 09/17/2020 12:00 AM ET)
Today's Range
Now: $4.78
50-Day Range
MA: $5.01
52-Week Range
Now: $4.78
Volume102,731 shs
Average Volume200,104 shs
Market Capitalization$174.03 million
P/E RatioN/A
Dividend YieldN/A
There is no company description available for Axcella Health Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:AXLA



Sales & Book Value

Annual SalesN/A
Book Value$2.61 per share


Net Income$-59,040,000.00


Market Cap$174.03 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
+0.05 (+1.06 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXLA News and Ratings via Email

Sign-up to receive the latest news and ratings for AXLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Axcella Health (NASDAQ:AXLA) Frequently Asked Questions

How has Axcella Health's stock been impacted by COVID-19 (Coronavirus)?

Axcella Health's stock was trading at $3.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AXLA shares have increased by 43.8% and is now trading at $4.7750.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Axcella Health?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Axcella Health

When is Axcella Health's next earnings date?

Axcella Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Axcella Health

How were Axcella Health's earnings last quarter?

Axcella Health Inc (NASDAQ:AXLA) posted its earnings results on Wednesday, August, 5th. The company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.56) by $0.08.
View Axcella Health's earnings history

What price target have analysts set for AXLA?

5 equities research analysts have issued 12-month target prices for Axcella Health's shares. Their forecasts range from $9.00 to $25.00. On average, they anticipate Axcella Health's share price to reach $15.80 in the next year. This suggests a possible upside of 230.9% from the stock's current price.
View analysts' price targets for Axcella Health

Are investors shorting Axcella Health?

Axcella Health saw a decline in short interest in August. As of August 14th, there was short interest totaling 269,700 shares, a decline of 36.7% from the July 30th total of 425,900 shares. Based on an average daily volume of 322,400 shares, the short-interest ratio is currently 0.8 days. Currently, 2.0% of the company's stock are sold short.
View Axcella Health's Short Interest

Who are some of Axcella Health's key competitors?

What other stocks do shareholders of Axcella Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Occidental Petroleum (OXY), VBI Vaccines (VBIV), Coty (COTY), Energy Transfer LP Unit (ET), Evofem Biosciences (EVFM), Main Street Capital (MAIN), Myovant Sciences (MYOV) and Pfizer (PFE).

When did Axcella Health IPO?

(AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink served as the underwriters for the IPO.

What is Axcella Health's stock symbol?

Axcella Health trades on the NASDAQ under the ticker symbol "AXLA."

Who are Axcella Health's major shareholders?

Axcella Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Flagship Pioneering Inc. (34.43%), FMR LLC (14.75%), Artal Group S.A. (2.47%), Monashee Investment Management LLC (0.62%), Marshall Wace LLP (0.33%) and EAM Investors LLC (0.25%). Company insiders that own Axcella Health stock include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet and Ventures Fund Iv LP Flagship.
View institutional ownership trends for Axcella Health

Which institutional investors are buying Axcella Health stock?

AXLA stock was purchased by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., FMR LLC, Artal Group S.A., Monashee Investment Management LLC, Marshall Wace LLP, EAM Investors LLC, Jacobs Levy Equity Management Inc., and Nuveen Asset Management LLC. Company insiders that have bought Axcella Health stock in the last two years include Catherine A Sohn, D Clay Bretches, David R Epstein, Laurent Chardonnet, and Ventures Fund Iv LP Flagship.
View insider buying and selling activity for Axcella Health

How do I buy shares of Axcella Health?

Shares of AXLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Axcella Health's stock price today?

One share of AXLA stock can currently be purchased for approximately $4.78.

How big of a company is Axcella Health?

Axcella Health has a market capitalization of $174.03 million. The company earns $-59,040,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

What is Axcella Health's official website?

The official website for Axcella Health is www.axcellahealth.com.

How can I contact Axcella Health?

Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-320-2200.

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.